CVR 30564782Public limited company (A/S)Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721900)København KFounded 23 Mar 2007
Employees
2
CVR, 2007
CVR registers no owner holding 5% or more.
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about SPREE PHARMA A/S, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexCVR registers no owner holding 5% or more.
Wyle David Solomonuntil 9 Jul 2010
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
CVR lists no current officers for this company.
Founded 23 Mar 2007.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
Q3 2010, quarterly: no employee count, 0 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | 2007 | Q1 2008 | Q2 2008 | Q4 2009 | Q1 2010 | Q2 2010 | Q3 2010 |
|---|---|---|---|---|---|---|---|
| Employees | 2 | No count | No count | No count | No count | No count | No count |
| FTE | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Series | Annual | Quarterly | Quarterly | Quarterly | Quarterly | Quarterly | Quarterly |
The legal entity's headcount in CVR, not the annual report's average, which may cover a group.
Source: CVR, latest Q3 2010, published 31 Mar 2011.
Not available in the CVR filing: the annual reports carry no machine-readable figures.
Annual report 2010
Published 11 Jul 2011
Annual report 2009
Published 17 May 2010
Annual report 2008
Published 18 May 2009
Annual report 2007
23 Mar 2007 to 31 Dec 2007, published 27 May 2008
No changes since Dandex began following this company. For announcements from before then, see Registrations.
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
What Pro holds for SPREE PHARMA A/S:
Have Pro? Sign in.
Amounts in DKK.
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| FoundingNot read from the announcement | None | None | None | 12,131,699 |
Source: Erhvervsstyrelsen's announcements, shown where the amounts add up to the registered capital.
Source: CVR, read 19 Nov 2026.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 19 Nov 2026.
9 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Likvidation sluttet, og selskabet opløst.
Ny adresse:
c/o Nielsen Nørager, Frederiksberggade 16, 1459 København K.
Likvidation vedtaget 09.07.2010.
Tiltrådt som likvidator:
Advokat Jakob Mosegaard Larsen, 1459 København K, den 09.07.2010.
Ledelsen fratrådt.
Selskabet tegnes af likvidator alene.
Selskabets kreditorer opfordres til at anmelde deres krav til likvidator. Krav skal anmeldes senest tre måneder fra dags dato.
Vedtægter ændret:
09.07.2010.
Direktion:
Udtrådt af direktionen:
Christian Karsten Hansen, den 08.07.2009.
Indtrådt i direktionen:
Wyle David Solomon (adm. dir), den 08.07.2009.
Bestyrelse:
Udtrådt af bestyrelsen:
Christian Karsten Hansen, den 18.05.2009.
Indtrådt i bestyrelsen:
Wyle David Solomon, den 18.05.2009.
Kapitalen er opdelt i klasser:
A kr. 6.824.080,00, B kr. 5.307.619,00.
Stiftelsesdato:
23.03.2007.
Seneste vedtægtsdato:
23.03.2007.
Kapital:
kr. 12.131.699,00.
Indbetalingsmåde:
kontant kr. 5.307.619,00 til kurs 105,00, i værdier kr. 6.824.080,00 til kurs 105,00.
Stiftere:
CVR-NR. 29150397 NORDIC BIOTECH VENTURE FUND II K/S, Østergade 5, 3., 1100 København K, den 23.03.2007, iCeutica Inc, den 23.03.2007.
Bestyrelse:
Direktør Florian Schønharting (formand), den 23.03.2007, osagie imasogie, den 23.03.2007, Mathew Callahan, den 23.03.2007, Direktør Christian Karsten Hansen, den 23.03.2007.
Direktion:
Direktør Christian Karsten Hansen (adm. dir), den 23.03.2007.
Selskabet tegnes af bestyrelsens formand i forening med en direktør eller af den samlede bestyrelse.
Revision:
CVR-NR. 24213714 DELOITTE STATSAUTORISERET REVISIONSAKTIESELSKAB, Weidekampsgade 6, 2300 København S, den 23.03.2007.
Første regnskabsår:
23.03.2007 - 31.12.2007.
Regnskabsår:
01.01 - 31.12.
P-number 1013215436Frederiksberggade 16, 1459 København K